Demonstration and comparative evaluation (including cost effectiveness) of tertiary technologies using micro-strainer filter/UV radiation, ultrafiltration, and sonolysis
of ozone; and
The kinetic experiments of pH-independent hydrolysis of 4-NPCA and sonolysis
of 4-NP were carried out without sonication and under ultrasound to test the online system.
A study involving sonolysis
, electro-oxidation and the use of hydrogen peroxide in various arrangements has been performed that successfully led to the development of the two-step treatment scheme.
Evan Unger, MD, FACR, president and CEO of ImaRx said, "This is an exciting milestone for us in developing SonoLysis
for vascular thrombosis in patients.
Aromatic compound degradation in water using a combination of sonolysis
Although based on a small number of patients, these findings further demonstrate the promise of our SonoLysis
therapy for the treatment of ischemic stroke," said Bradford Zakes, President and Chief Executive Officer of ImaRx Therapeutics.
Zakes stated, "While these recent events are disappointing, we believe there is significant value in our urokinase business, SonoLysis
program and other assets.
This decrease was principally a result of reduced headcount and third party service costs and other expenses related to our refined focus on development of our SonoLysis
programs and the removal of expenses associated with the recombinant thrombolytic drug assets that the company elected to relinquish to Abbott Laboratories in December 2006, partially offset by increased clinical trial expenses.
Identified strategic funding to continue advancement of its core SonoLysis
program upon closing of urokinase divestiture with Microbix Biosystems.
This research collaboration represents a significant step forward for ImaRx's SonoLysis
program," said Bradford A.
Through this transaction, ImaRx will have gained access to operating capital under favorable economic terms that will enable the company to continue the advancement of our core SonoLysis
2007 Year in Review: -- Initiated TUCSON Phase I/II clinical study -- Received FDA approval to market urokinase under new trade name Kinlytic(TM) -- Signed strategic licensing agreement with Bracco International -- Completed Initial Public Offering -- Awarded Phase I STTR grant from the National Institutes of Health -- Signed research collaboration with Royal Philips Electronics -- Extended expiration dating of urokinase product inventory Key Corporate Highlights: PhaseI/II TUCSON Clinical Trial and SonoLysis